Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy

After a decade of cancer immunotherapy (both active and adoptive), based on the use of well-defined tumor-associated antigens (TAA), and despite the large amount of new information that has been collected both in preclinical and clinical settings, the clinical outcome of immunotherapy trials has

[1]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[2]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[3]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[4]  M. Clarke,et al.  Cancer stem cells: models and concepts. , 2007, Annual review of medicine.

[5]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[6]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[7]  G. Gaudernack,et al.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study , 2006, British Journal of Cancer.

[8]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[9]  A. Anichini,et al.  Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy , 2006, Clinical Cancer Research.

[10]  Peter T Masiakos,et al.  Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Rieber,et al.  Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial , 2006, The Prostate.

[12]  Thierry Boon,et al.  Human T cell responses against melanoma. , 2006, Annual review of immunology.

[13]  H. Li,et al.  Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.

[14]  S. Aamdal,et al.  Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer , 2006, Cancer Immunology, Immunotherapy.

[15]  G. Damonte,et al.  Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. , 2006, Blood.

[16]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[17]  C. Huber,et al.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Elder,et al.  A tumorigenic subpopulation with stem cell properties in melanomas. , 2005, Cancer research.

[19]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[20]  Mads Hald Andersen,et al.  Regulators of apoptosis: suitable targets for immune therapy of cancer , 2005, Nature Reviews Drug Discovery.

[21]  F. Lozupone,et al.  Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? , 2005, Expert opinion on biological therapy.

[22]  Donna Niedzwiecki,et al.  Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.

[23]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[24]  J. Becker,et al.  Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. , 2005, Vaccine.

[25]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[26]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[27]  S. Rosenberg,et al.  Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing Telomerase , 2004, Clinical Cancer Research.

[28]  W. Hahn,et al.  Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes , 2004, Clinical Cancer Research.

[29]  P. Dalerba,et al.  The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. , 2003, Cancer research.

[30]  L. Kanz,et al.  Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. , 2003, Blood.

[31]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Gilboa,et al.  Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. , 2002, Cancer research.

[33]  Francesco M Marincola,et al.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.

[34]  Jingwu Z. Zhang,et al.  Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. , 2002, Cancer research.

[35]  W. Hahn,et al.  Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. , 2001, Cancer research.

[36]  J. Becker,et al.  Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. , 2001, Cancer research.

[37]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[38]  E. Thiel,et al.  Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. , 2000, Cancer research.

[39]  H. Rammensee,et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.

[40]  J. Hipp,et al.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Altieri,et al.  Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[42]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[43]  C. Farina,et al.  Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage , 1998, The Journal of experimental medicine.

[44]  S. Rosenberg,et al.  The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. , 1997, Journal of immunology.

[45]  J. Bryant,et al.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.

[46]  F. Brasseur,et al.  A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.

[47]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[48]  A. Anichini,et al.  Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones , 1986, The Journal of experimental medicine.

[49]  M. Carpenter,et al.  Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. , 2004, Vaccine.

[50]  J. Diebold,et al.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. , 1998, The American journal of pathology.